DDW_Benchling & BIO-RAD_Logo_400px copy
Therapuetic Antibodies webinar speakers_images_200px copy
In this webinar, you will hear from Dr Jill O'Donnell-Tormey, CEO and Director of Scientific Affairs at Cancer Research Institute; Dr Sheila Keating, VP of Immunology at Gigagen; as well as event sponsors Dr Milind Nigam, Leader - Scientific Solutions Consulting at Benchling, and Dr Paola Genevini, Technical Sales Specialist at Bio-Rad.
Dr O'Donnell-Tormey will address the opportunities, innovations and challenges in the therapeutic antibody space. Dr Keating will discuss impediments to monoclonal successes - the time and money needed for discovering, manufacturing, efficacy testing and acquiring regulatory approval for each individual mAb. Dr Nigam will outline the role of software in accelerating the pace of discovery of antibody therapeutics while Dr Genevini will discuss the generation of recombinant tool antibodies to support cell and gene therapy development.
What you will learn:
  • Where is the opportunity in the mAb market and where is the market heading?
  • How extensive is innovation and opportunity – where are we likely to see evolution?
  • What effect has antibody engineering had on drug discovery and development?
  • What are the main drivers and challenges for the market in the next ten years?

An audience Q&A session with the presenters follows the webinar presentations.

Watch the webinar on-demand now!

Watch the Webinar